Wearable health technology

State of the art (2026)

By 2026 wearables have crossed from fitness trackers to FDA-cleared consumer medical devices. The Apple Watch Series 11 (September 2025) added passive hypertension-alert detection on top of ECG and FDA-cleared sleep-apnea notifications; Samsung's Galaxy Watch added cuffless blood-pressure tracking and the Oura Ring Gen 4 added sleep-apnea screening. Over-the-counter continuous glucose monitoring has opened the non-diabetic market – Dexcom's Stelo and Abbott's Lingo (both OTC-cleared 2024) sell direct to consumers, with Apple Watch and Oura displaying readings. The structural prize, non-invasive glucose, is still unsolved and targeted around 2027. The frontier is shifting from passive measurement to agentic health AI that flags risk and prompts intervention.

Apple Watch crossed from fitness to consumer medical device with hypertension clearance

Apple Watch Series 11 (launched 19 September 2025) carries the most significant FDA clearance in consumer wearables to date: passive hypertension-alert detection. The feature analyses blood-vessel response over 30-day windows using the optical heart sensor, alerts users on consistent patterns indicative of chronic high blood pressure, and is available on Series 9 and later plus Ultra 2 and later via watchOS 26. Hypertension affects approximately 1.3B adults globally and is largely undiagnosed in lower-income tiers; passive detection on the world's most-shipped premium smartwatch (Apple sells 40M+ Watches annually) is the largest single screening expansion in cardiovascular history by reach. Combined with the existing AF (Series 4+, 2018), ECG (Series 4+), sleep-apnoea detection (Series 9+, watchOS 11), and blood-oxygen monitoring, Apple Watch now passes the threshold from quantified-self category into a regulated consumer medical-device category. Samsung Galaxy Watch and Fitbit are following with their own hypertension and ECG features.

OTC continuous glucose monitoring is opening the non-diabetic market

Continuous glucose monitoring (CGM) has been a Type-1 and insulin-using-Type-2 diabetic category for the past decade. Dexcom Stelo (FDA-cleared OTC, 2024) and Abbott Lingo broke the prescription requirement and aimed at the non-diabetic wellness market. Stelo is targeting 5M+ users globally by end-2026; combined with Lingo, the OTC CGM segment is the fastest-growing wearable medical-device sub-category. The Oura ring integrates Stelo data; Whoop MG has positioned around metabolic-health metrics. In January 2026 the FDA published wellness exemptions for validated glucose readings on wellness-intended devices, accelerating the regulatory pathway for non-diabetic CGM. The structural read: subscription-recurring CGM revenue at non-diabetic-population scale is materially larger than the historical diabetic-only TAM, and the incumbent CGM duopoly (Dexcom + Abbott) sustains share even as consumer-platform companies layer interpretation and coaching above.

Non-invasive glucose monitoring is the structural prize, targeted ~2027

The unsolved frontier in wearable health is non-invasive continuous glucose monitoring - a wrist-worn or patch-based sensor that eliminates subcutaneous insertion. Apple is developing an optical-based non-invasive glucose technology that has been in internal trials for years; Samsung is working on a Raman-spectroscopy approach; multiple startups (Know Labs, Nemaura, Movano) are progressing through clinical trials. None has shipped a commercial product as of 2026. The commercial launch of any consumer-grade non-invasive CGM by Apple, Samsung, or a credible third-party (likely 2027 at earliest) would be the largest single product launch in wearable health and could expand the addressable market from diabetic-plus-curious-wellness to the entire smartwatch installed base. The constraint is sensor accuracy (commercial-grade ±10-15% MARD vs invasive CGMs at ±9%), regulatory clearance, and form-factor manufacturability at scale.